Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Viro-Immunologic Effects of Interrupting Maraviroc in Patients Failing a Maraviroc-containing Antiretroviral Treatment (The Maraviroc Short-Stop Study) [Studio degli effetti immuno-virologici dell'interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc]

Trial Profile

Viro-Immunologic Effects of Interrupting Maraviroc in Patients Failing a Maraviroc-containing Antiretroviral Treatment (The Maraviroc Short-Stop Study) [Studio degli effetti immuno-virologici dell'interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc]

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maraviroc (Primary) ; Abacavir; Atazanavir; Darunavir; Didanosine; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Fosamprenavir; Lamivudine; Lamivudine/abacavir; Lamivudine/zidovudine; Lopinavir; Nevirapine; Raltegravir; Ritonavir; Saquinavir; Stavudine; Tenofovir disoproxil fumarate; Tipranavir; Zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms The Maraviroc Short-Stop Study
  • Most Recent Events

    • 25 Jul 2012 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top